Evidence map›Paper›PMID 42130715›Full record

ArticleACS pharmacology & translational science2026

Blood-Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma.

Xiaotong Zhao, Yaxin Li, William R Martin, Fatma Salem, Ruchitha Korem, Soha Bolbol, Garrett Worden, Maheen Sajid, Alia Al-Rousan, Blake Wilt and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiaotong ZhaoDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Yaxin LiDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
William R MartinDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.ORCID https://orcid.org/0000-0003-0616-0462
Fatma SalemDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Ruchitha KoremDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Soha BolbolDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Garrett WordenDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Maheen SajidDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Alia Al-RousanDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Blake WiltDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Wenjing ZhangDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Lyubomyr TurchynAnimal Research Facility, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Christopher HubertDepartment of Biochemistry, School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, Ohio 44106, United States.
Liqun NingDepartment of Mechanic Engineering, College of Engineering, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.ORCID https://orcid.org/0000-0002-3651-7410
Justin D LathiaDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio 44195, United States.
Aimin ZhouDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Bin SuDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Sciences and Health Professions, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.ORCID https://orcid.org/0000-0002-0711-441X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen receptor (AR) contributes to the progression of glioblastoma (GBM), which is consistent with the sex difference in GBM, which has a higher incidence in males than in females. Therefore, targeting AR is a potential therapeutic approach for GBM treatment. However, AR mutation commonly occurs in GBM, which makes conventional AR antagonists less effective. AR degraders abolish AR at the protein level regardless of the mutation status of AR, which makes it a better strategy in GBM. Compound

Indexed as

androgen receptorBBBglioblastomaprotein degradationsex disparity

Identifiers

PMID42130715
PMCPMC13162162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.